These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21289309)

  • 1. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
    Shaughnessy JD; Qu P; Usmani S; Heuck CJ; Zhang Q; Zhou Y; Tian E; Hanamura I; van Rhee F; Anaissie E; Epstein J; Nair B; Stephens O; Williams R; Waheed S; Alsayed Y; Crowley J; Barlogie B
    Blood; 2011 Sep; 118(13):3512-24. PubMed ID: 21628408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
    Stessman HA; Lulla A; Xia T; Mitra A; Harding T; Mansoor A; Myers CL; Van Ness BG; Dolloff NG
    Leukemia; 2014 Nov; 28(11):2263-7. PubMed ID: 25005244
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
    Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
    Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
    Shuqing L; Jianmin Y; Chongmei H; Hui C; Wang J
    Exp Hematol; 2011 Dec; 39(12):1117-8. PubMed ID: 21920470
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
    Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
    Stessman HA; Baughn LB; Sarver A; Xia T; Deshpande R; Mansoor A; Walsh SA; Sunderland JJ; Dolloff NG; Linden MA; Zhan F; Janz S; Myers CL; Van Ness BG
    Mol Cancer Ther; 2013 Jun; 12(6):1140-50. PubMed ID: 23536725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.